Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Record Q1 results:

<< Previous

Bullboard Posts

Next >>

Comment by wizzdumbon Feb 10, 2022 11:15am

124 Views

Post# 34416641

RE:RE:Record Q1 results:

Looks like QAPs is maxed out at about $1.1M last three quarters now although Q2 2021 was a bit higher. I assume this is their current capacity limit. Will be interesting to see how high this can go once the expansion is complete in Spring. We probably won't see the true fruits of this until Q4 2022.

<< Previous

Bullboard Posts

Next >>

MDA Space stock blasts off on Q3 financial results